{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000033","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.777323+00:00","generated_at":"2026-06-03T22:13:31.647763+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Akebia extends vadadustat supply agreement with STA to 2029","bullets":["Amendment #2 extends Supply Agreement term to April 2, 2029 (five additional years).","Agreement covers manufacturing of vadadustat drug substance for commercial purposes.","Volume-based pricing structure was amended; no financial terms disclosed.","Original Supply Agreement dated April 2, 2020, previously amended April 15, 2021.","Contract manufacturer STA Pharmaceutical Hong Kong Limited."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000033","json":"https://secwatch.observer/filing/0001517022-24-000033.json","markdown":"https://secwatch.observer/filing/0001517022-24-000033.md","text":"https://secwatch.observer/filing/0001517022-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/0001517022-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/akba-20241504xwuxiamendment.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:13:31.647763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8cd0e1d07542310d7d898e13e3e2193d02bd54cc","claim":"Akebia Therapeutics, Inc. amended Amendment #2 to the Supply Agreement with STA Pharmaceutical Hong Kong Limited (effective 2024-04-15).","evidence_excerpt":"(the “Company”) entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation (“STA”), as amended on April 15, 2021 (as amended, the “Supply Agreement”), under which STA manufactures vadadustat drug substance (“Product”) for the Company’s commercial purposes.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/0001517022-24-000033-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"STA Pharmaceutical Hong Kong Limited"},{"label":"Effective","value":"2024-04-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}